ProRx LLC FDA Record
- Latest inspection OAI · Sep 19, 2025
- Last warning letter 2026
ProRx LLC has 14 FDA recalls, 2 inspections, 0 510(k) clearances and 2 compliance actions on record. FDA has issued 3 warning letters to ProRx LLC, the most recent on Apr 7, 2026. FDA has published 2 Form 483s for ProRx LLC.
- Latest recall
- D-0118-2026 · Class II · Oct 15, 2025
- Latest inspection
- Sep 19, 2025 · OAI
Summary
| Records | Count | Last refreshed | Source as of | Status |
|---|---|---|---|---|
| Recalls | 14 | Nov 15, 2026 | File dated Nov 10, 2026 | Current |
| 510(k) clearances | 0 | Nov 15, 2026 | File dated Nov 9, 2026 | Current |
| Inspections | 2 | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Compliance actions | 2 | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
FDA record by year
ProRx LLC: FDA inspections per year
| Year | Inspections | OAI | Warning letters | Recall records | Class I |
|---|---|---|---|---|---|
| 2026 | 0 | 0 | 1 | 0 | 0 |
| 2025 | 1 | 1 | 0 | 7 | 0 |
| 2024 | 1 | 1 | 1 | 7 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2020 | 0 | 0 | 0 | 0 | 0 |
| 2019 | 0 | 0 | 0 | 0 | 0 |
| 2018 | 0 | 0 | 0 | 0 | 0 |
| 2017 | 0 | 0 | 0 | 0 | 0 |
Reviewing ProRx LLC as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check ProRx LLC yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
ProRx LLC FDA Warning Letters
| Issued | Subject | Issuing office | Close-out letter |
|---|---|---|---|
| Apr 7, 2026 · Letter on fda.gov | Compounding Pharmacy/Adulterated Drug Products | Center for Drug Evaluation and Research (CDER) | |
| Mar 4, 2025 · Letter on fda.gov | Compounding Pharmacy/Adulterated Drug Products | Center for Drug Evaluation and Research (CDER) | |
| Dec 20, 2024 · Record page |
ProRx LLC Form 483s
| Date | Document | FEI |
|---|---|---|
| Sep 19, 2025 · Document on fda.gov | 483 | 3022250654 |
| Aug 2, 2024 · Document on fda.gov | 483 | 3022250654 |
Recent recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0118-2026 | Class II | Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd… | Oct 15, 2025 |
| D-0117-2026 | Class II | Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only… | Oct 15, 2025 |
| D-0115-2026 | Class II | Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only… | Oct 15, 2025 |
| D-0114-2026 | Class II | Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd… | Oct 15, 2025 |
| D-0119-2026 | Class II | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd… | Oct 15, 2025 |
| D-0120-2026 | Class II | Tirzepatide Injection, 27 mg/3 mL (9 mg/mL), 3mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd… | Oct 15, 2025 |
| D-0116-2026 | Class II | Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only… | Oct 15, 2025 |
| D-0652-2024 | Class II | SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by… | Aug 22, 2024 |
| D-0651-2024 | Class II | Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product… | Aug 22, 2024 |
| D-0656-2024 | Class II | TIRZEPATIDE 60 mg/3mL (20/mg/mL), Rx Only, 3mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341… | Aug 22, 2024 |
| D-0654-2024 | Class II | Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx… | Aug 22, 2024 |
| D-0653-2024 | Class II | SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX… | Aug 22, 2024 |
| D-0655-2024 | Class II | TIRZEPATIDE 20 mg/2mL (10/mg/mL), Rx Only, 2mL Multiple Dose Vial, Mfd by: ProRx Exton, PA, 19341… | Aug 22, 2024 |
| D-0650-2024 | Class II | Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx… | Aug 22, 2024 |
Recent FDA inspections
| Date | Site | Product | Classification | FEI |
|---|---|---|---|---|
| Sep 19, 2025 | Exton, PA | Drugs | Official Action Indicated (OAI) | 3022250654 |
| Aug 2, 2024 | Exton, PA | Drugs | Official Action Indicated (OAI) | 3022250654 |
- NAI
- No objectionable conditions or practices were found during the inspection.
- VAI
- Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
- OAI
- Regulatory and/or administrative actions are recommended.
Compliance Actions
FDA's compliance actions data lists 2 compliance actions under ProRx LLC: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.
FDA-inspected facilities
| Facility | Location | Inspections | Latest |
|---|---|---|---|
| FEI 3022250654 | Exton, PA | 2 | Sep 19, 2025 |
ProRx LLC and the FDA: common questions
Has ProRx LLC received an FDA warning letter?
Yes. FDA has issued 3 warning letters to ProRx LLC. The most recent is dated Apr 7, 2026, with the subject "Compounding Pharmacy/Adulterated Drug Products".
Has ProRx LLC received an FDA Form 483?
FDA has published 2 Form 483s for ProRx LLC in its reading room, the most recent dated Sep 19, 2025. FDA publishes some Form 483s, not all of them.
When did the FDA last inspect ProRx LLC?
The most recent FDA inspection on file ended Sep 19, 2025 at Exton, PA and was classified OAI. FDA has 2 inspections of ProRx LLC on file, 2 of them classified OAI (official action indicated).
Has ProRx LLC had an FDA recall?
Yes. ProRx LLC has 14 FDA recalls on record. The most recent started Oct 15, 2025.
Need more than this page shows? Ask about ProRx LLC in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.